Loading
Life sciences · Journal article
Cancer Cell International · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background Cancer-associated fibroblasts (CAFs) are instrumental in tumor progression by interacting with tumor cells, other stromal components, and the extracellular matrix (ECM) within the tumor stroma. Main body The origin, heterogeneity, and activation mechanisms of CAFs in different cancer types have been widely reported. Their roles and mechanisms of therapeutic resistance in colorectal cancer (CRC) have only recently been explored. This review presents the most relevant evidence on CAF biology in CRC, including their subtypes, markers, role in ECM remodeling, and roles in signaling pathways associated with therapeutic failure and tumor progression. We further consider the contribution of CAFs to therapeutic resistance, highlighting potential agents from preclinical studies and clinical trials targeting CAFs in CRC. Based on the most recent findings, we consider the potential of targeting CAFs as a strategy to disrupt the tumor-supportive microenvironment and improve therapeutic efficacy. Conclusions The review highlights key advances in the field that may contribute to improving the survival of patients with CRC and similar cancers, particularly those showing resistance to classic therapies such as chemotherapy and radiotherapy.